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Guest Editorial
Atrial Fibrillation Screening in Hong Kong − Where Are We Now?
NGAI-YIN CHAN
Deputy Chief-of-Service, Department of Medicine & Geriatrics, Princess Margaret Hospital, Hong Kong

Atrial fibrillation (AF) is the most common
sustained heart rhythm disorder1 and has become a
global epidemic especially in the developed countries
with aging population. Although the risk of AF-related
stroke can be markedly reduced by 64-70% by oral
anticoagulation therapy,2 a major challenge remains to
be the evasive nature of the condition to be diagnosed
early for effective treatment. Around a quarter of patients
have silent or asymptomatic AF3 and up to 25% of
patients with AF-related stroke have AF diagnosed only
at the time of stroke.3-5
According to the WHO criteria, a disease is
suitable for screening when it is an important health
problem with an accepted treatment, there are facilities
for diagnosis and treatment, there is a latent and
symptomatic stage, the natural history is understood,
there is an agreed policy on whom to treat, the cost of
finding is economically balanced with overall health,
the case finding is a continuous process and the
screening test is suitable and acceptable to the
population.6 AF satisfies most of those criteria and
currently the European Society of Cardiology
recommends opportunistic screening for AF by pulse
taking or electrocardiogram rhythm strip in patients over
65 years of age.2 Screening for AF in different settings
and with different tools have been studied7 and in recent
few years, researchers in Hong Kong have contributed
significantly to the knowledge base in this area.

Address for reprints: Dr Ngai-yin Chan
Room 223, Block J, Princess Margaret Hospital, 2-10 Princess
Margaret Hospital Road, Kowloon, Hong Kong
Email: ngaiyinchan@yahoo.com.hk
Opinions expressed are views of the authors and not necessarily the
view of the editorial board or the Hong Kong College of Cardiology.
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There were 2 large-scale community-based
systematic screening programs carried out in Hong Kong
in recent years.8,9 In both studies, Kardia mobile device,
capable of producing a single-lead wireless smartphone
electrocardiogram (sECG) for 30 seconds was used as
the tool for screening.10 Chan et al reported a study
aiming to assess the feasibility of community screening
for AF using sECG and to generate epidemiological data
on the prevalence and risk factors of AF in Hong Kong.8
All citizens aged 18 or above were eligible for
participation. Among 13,122 (mean age 64.7) citizens,
101 (0.8%) had newly diagnosed AF with 66 (65.3%)
being asymptomatic. The mean CHA2DS2VASc score
was 3.1 in patients with newly diagnosed AF. The
number-needed-to-screen (NNS) for one newly
diagnosed AF was 129. AF was detected with sECG in
239 (1.8%) citizens and it was likely persistent AF. Apart
from those patients, 872 (6.6%) citizens self-reported
history of AF without sECG showing it and this likely
represents paroxysmal AF. The independent predictors
of AF shown in this study included increasing age and
height, history of heart failure, valvular heart disease,
stroke, hyperlipidaemia, coronary artery disease,
peripheral artery disease and cardiothoracic surgery.
Chan et al further examined the effectiveness of another
community-based AF screening program named the
AFinder program, the results of which were recently
presented in a late-breaking session of the European
Society of Cardiology Congress 2017.9 The AFinder
program was characterized by being initiated by a panel
of cardiologists, led by the Hong Kong Council of Social
Service which was a non-governmental organization,
and carried out by a group of trained layperson
volunteers. All citizens aged 50 or above were eligible
for participation. Among 10,735 (mean age 78.6)
citizens screened with interpretable sECG's, 244 (2.3%)
had AF and 74 (0.69%) had newly diagnosed AF. The
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mean CHA2DS2VASc score was 3.9 in patients with
newly diagnosed AF. The NNS for one newly diagnosed
AF was 145. A nurse performed a 9-month phone
follow-up on those patients with AF and assessed the
health-seeking behavior of them and for those indicated,
whether they were given oral anticoagulation and their
compliance. Among 72 patients with newly diagnosed
AF and indication for oral anticoagulation, only 47
(65%) of them sought medical attention and more
disappointingly, only 17 (24%) of them were prescribed
oral anticoagulation. Once they were given oral
anticoagulation, most of them (16, 94%) reported 100%
compliance to therapy. Compared with the NNS for one
newly diagnosed AF, the NNS for one patient receiving
appropriate oral anticoagulation for newly diagnosed
AF increased 3.6-fold to 671. This seriously underscores
the utmost importance of a more structured downstream
management pathway being embedded in any AF
screening program. The potential of Kardia mobile
device for auto-screening for AF has also been assessed
in this study. The sensitivity and specificity of the
automated algorithm in diagnosing AF were 75% and
98.2% respectively. The positive predictive value and
negative predictive value were 64.9% and 99.5%
respectively. The suboptimal sensitivity of the current
version of algorithm limits its application in autoscreening.
Screening for AF has also been studied in the
primary care setting in Hong Kong and different tools
have been used.11,12 Chan and Siu et al used a smartphone
camera-based device capable of diagnosing AF by
measuring photoplethysmographic pulse waveform for
AF screening in a primary care setting.11 Patients with
hypertension and/or diabetes mellitus or were ≥65 years
of age were screened. AF was found in 28 (2.76%) of
1,013 participants and 5 (0.5%) had newly diagnosed
AF. The sensitivity and specificity of the automated
algorithm of the device were 92.9% and 97.7%
respectively. The positive and negative predictive value
were 53.1% and 99.8% respectively. The same group
of researchers reported the use of another device, an
automated blood pressure measurement device which
is capable of generating an irregularity index based on
R-R intervals, for AF screening, again in the primary
care setting.12 Similar to the study described above, they
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screened patients with hypertension and/or diabetes
mellitus or who were ≥65 years of age. In 5,969 patients
recruited, AF was diagnosed in 72 (1.2%) of them. The
proportion of patients with newly diagnosed AF was
however not mentioned. The sensitivity and specificity
of this device in diagnosing AF were 80.6% and 98.7%
respectively. The positive and negative predictive value
were 42.4% and 99.8% respectively. The overall
diagnostic performance as determined by area under
curve was 0.90.
AF screening program has also been carried out
in specialist medical outpatient clinic in Hong Kong.13
Yan et al screened 9,046 (mean age 72.1) patients with
the Kardia mobile device and identified 121 (1.5%)
patients with newly diagnosed AF, all of whom had
CHA 2DS 2VASc score ≥2. In addition, the overall
prevalence of AF was 9.4% (850/9,046) in this screened
population.
Although increasing data has become available
in AF screening in recent years, the questions on what
the most appropriate setting is and what the best tool
should be remain. Obviously, many of us are looking
forward to large and appropriately-powered randomized
outcome studies to answer the above questions and in
addition, to confirm that systematic AF screening
programs can indeed reduce the burden of stroke and
the consequent mortality. In Hong Kong, different
groups of researchers studied AF screening in different
settings and with different tools. However, they have
the same passion and vision of reducing the burden of
stroke and the consequent disability and deaths in Hong
Kong. For any AF screening program to be sustainable,
it is essential, at some point in time, to seek support
from the government. In Hong Kong, we are now
probably at that critical juncture.
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ICSM, THE TWENTY FIRST ANNUAL SCIENTIFIC MEETING
ABSTRACTS
Abstracts for Invited Lectures:
IL1.
CARDIOVASCULAR MANIFESTATION IN SYSTEMIC
INFLAMMATORY DISORDERS
KH Yiu
Department of Medicine, The University of Hong Kong, Hong Kong
Systemic inflammatory diseases, including those of rheumatology and
dermatology, are associated with increased cardiovascular events. Multiple
evidences suggested that the chronic systemic inflammation may play a pivotal
role in all stages of atherosclerotic plaque formation, from initiation of the
fatty streak to plaque rupture and consequent acute coronary syndrome in
those diseases. By using different cardiovascular imaging modalities, a
number of studies have been completed to investigate the disease pattern,
pathophysiology and clinical outcomes of cardiovascular manifestation in
patients with systemic inflammatory disorders. By identifying those who
had premature cardiovascular disease using advanced imaging technique may
improve risk-stratification. Finally, future studies should focus on the
relationship between the cumulative burden of inflammation and
cardiovascular disease development, and the effects of aggressive treatment
on the long-term cardiovascular outcome of these patients.

IL4.
MECHANOSENSITIVE TRP CHANNELS IN
CARDIOVASCULAR SYSTEM
XQ Yao
School of Biomedical Sciences and Li Ka Shing Institute of Health Science,
The Chinese University of Hong Kong, Hong Kong
Accumulating amount of evidence suggests that transient receptor potential
(TRP) channels may function as cellular sensors to perceive and respond to a
variety of mechanical stimuli including stretch, hydrostatic pressure and fluid
flow. In cardiovascular system, cardiomyocytes are constantly subjected to
cyclic stretch due to heart contraction and relaxation during cardiac cycle.
On the other hand, vascular endothelial cells lining the blood vessels are
exposed to hemodynamic shear force generated by blood flow. In addition,
arterial baroreceptors serve as a frontline pressure sensor to detect blood
pressure in circulation system. Our group has been studying these
mechanosensors in cardiovascular system. With the use of human embryonic
stem cell-derived cardiomyocytes (hESC-CMs) as models, we studied the
uniaxial cyclic stretch in human cardiomyocytes. TRPV4 was found to be
expressed in these cardiomyocytes. 4α-phorbol 12,13-didecanoate (4α-PDD),
a TRPV4 agonist, elicited a cytosolic Ca2+ ([Ca2+]i) rise, the effect of which
was abolished by TRPV4 inhibitors RN1734 and HC067047. Importantly,
longitudinal stretch was found to induce a [Ca2+]i rise, the effect of which
was inhibited by TRPV4 antagonists. These data strongly suggest endogenous
TRPV4 channels as a mechanosensor for longitudinal stretch during cardiac
cycle. We further found important roles of TRPV4 in mediating cyclic stretchinduced realignment of hESC-CMs and disease progression of dilated
cardiomyopathy. We also explored the molecular identity of pressure sensor
in arterial baroreceptor, which serves as a frontline sensor to detect blood

J HK Coll Cardiol, Vol 25

pressure. We identified TRPC5 channels as one mechanical sensor in the
aortic and carotid baroreceptor. TRPC5 knockout mice showed diminished
pressure-induced action potential firing in the afferent nerve and baroreflexmediated heart rate reduction upon blood pressure elevation. Telemetric
measurement of the daily blood pressure demonstrated that TRPC5 knockout
mice displayed phenotype of severe blood pressure fluctuation. These studies
suggest that TRPC5 channels are a key pressure transducer in the baroreceptor
and plays an important role in maintaining blood pressure stability. This study
was supported by Hong Kong RGC Grants (Hong Kong RGC Grant T13706/11, AoE/M-05/12, RGC-NSFC Joint Grant N_CUHK439/13 and National
Science Foundation of China 14118516.
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ICSM, THE TWENTY FIRST ANNUAL SCIENTIFIC MEETING
ABSTRACTS
Abstracts for Invited Lectures:
IL5.
MATURE CARDIOMYOCYTES FROM HUMAN
PLURIPOTENT STEM CELLS FOR DRUG SCREENING
AND DISEASE MODELLING
NY Poon
School of Biomedical Sciences, Li Ka Shing Faculty of Medicine,
The University of Hong Kong, Hong Kong
Differentiation of human pluripotent stem cells (hPSCs) to the cardiac lineage
represents a potentially unlimited source of cardiomyocytes (CMs) for research
and clinical applications. Limitations to their use include their immature,
embryonic-like developmental state and their heterogeneity characterized by
mixed population of cells and poorly defined function. Using a unique strategy
for proteomics profiling, we identified proteins on the cell surface of hPSCCMs. Our dataset revealed an association between the expression of late
protein 1 (L1), a surface protein involved in metabolism, with a more advanced
differentiation stage, Viable CMs positive for this developmental marker can
be isolated by cell sorting and are more adult-like in their gene expression
pattern, morphology and functions. Our work provides important proof-ofprinciple for the isolation and characterisation of mature and defined hPSCCM subpopulations, and will greatly advance the use of hESC-derivatives
for medical research, disease modelling and drug testing.
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ICSM, THE TWENTY FIRST ANNUAL SCIENTIFIC MEETING
ABSTRACTS
Abstracts for Oral Presentation:
OP1.
NETWORK META-ANALYSIS OF CARDIOVASCULAR
OUTCOMES IN RANDOMISED CONTROLLED TRIALS OF
NEW ANTIDIABETIC DRUGS
Y Fei, MF Tsoi, CR Kumana, TT Cheung, BMY Cheung
Department of Medicine, The University of Hong Kong, Queen Mary Hospital,
Hong Kong

Conclusions: GLP-1 RAs and SGLT-2 inhibitors reduced the risk of MACE
and death. DPP-4 inhibitors were inferior to these two drug classes. SGLT-2
inhibitors were the best in reducing cardiovascular events among the three
drug classes, which can be considered as the prior second-line treatment for
T2D patients at high cardiovascular risks after metformin.

Objectives: Evidence directly comparing the effect of new antidiabetic drugs
on cardiovascular outcomes in patients with type 2 diabetes (T2D) in
randomised controlled trials (RCTs) was limited. We therefore assessed
cardiovascular safety of these drugs using network meta-analysis.
Methods: We searched MEDLINE, EMBASE, the Cochrane database, and
ClinicalTrials.gov for RCTs involving glucagon-like peptide-1 receptor
agonists (GLP-1 RAs), sodium-glucose co-transporter 2 (SGLT-2) inhibitors,
and dipeptidyl peptidase-4 (DPP-4) inhibitors. Those reported rates of major
adverse cardiovascular events (MACE) and deaths in T2D patients with
established cardiovascular risks were eligible to be included. Data were
analysed using R.
Results: Nine RCTs with altogether 72262 T2D patients were included for
analysis. Compared to placebo, GLP-1 RAs and SGLT-2 inhibitors reduced
MACE (OR 0.89, 95%CI 0.82-0.97 and OR 0.86, 95%CI 0.77-0.95,
respectively), all-cause mortality (OR 0.89, 95%CI 0.80-0.99 and OR 0.78,
95%CI 0.69-0.88, respectively) and cardiovascular mortality (OR 0.85, 95%CI
0.73-0.99 and OR 0.76, 95%CI 0.65-0.88, respectively). SGLT-2 inhibitors
were more beneficial than DPP-4 inhibitors in reducing MACE (OR 0.87,
95%CI 0.77-0.98) and cardiovascular mortality (OR 0.75, 95%CI 0.620.90). DPP-4 inhibitors, although were comparable to placebo, increased allcause mortality when compared to GLP-1 RAs (OR 1.16, 95%CI 1.01-1.33)
and SGLT-2 inhibitors (OR 1.31, 95%CI 1.13-1.53).

OP2.
EFFECTS OF AGE AND HYPERLIPIDEMIA ON
PROSTACYCLIN RECEPTOR-MEDIATED RELAXATIONS
YH Cheng, PM Vanhoutte, SWS Leung
Department of Pharmacology and Pharmac, Faculty of Medicine, The University
of Hong Kong, Hong Kong
The role of prostacyclin receptors (IP) in the consequences of ageing and
hyperlipidemia on vascular responsiveness was investigated in the aorta of
apolipoprotein E knockout (ApoE-/-; a well-established hyperlipidemic animal
model) mice and their wild-type counterparts (C57BL/6 mice). ApoE-/- mice
and age-matched wild-type mice were fed a normal or a high-fat highcholesterol diet for 29 weeks (starting at five weeks of age). Aortic rings
were contracted with phenylephrine and relaxed with cumulative additions
of increasing concentrations of iloprost (IP receptor agonist; 10-9-10-6 M),
acetylcholine (muscarinic agonist;10-10-10-5 M) or UK14304 (α2-adrenergic
agonist; 10-10-10-5 M). In young (five weeks old) wild-type mice, iloprost
caused IP receptor-, endothelial nitric oxide (NO) synthase (eNOS)-, and
soluble guanylyl cyclase (sGC)-dependent relaxations. Ageing (from five to
34 weeks) did not alter responses to iloprost but reduced relaxations to
acetylcholine and UK14304 without altering the sensitivity of the smooth
muscle to the NO donor detaNONOate. Western immunoblotting indicated
that the IP and thromboxane-prostanoid (TP) receptor presences were
comparable in aortae of young and older mice. While ageing combined with
high-fat diet did not affect the relaxations to acetylcholine and UK14304,
responses to iloprost were shifted from relaxations to contractions; the latter
were due to activation of TP receptors, coupled with reduced IP receptor
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presence. Apolipoprotein E (ApoE) was present in the aortae of wild-type
but not ApoE -/- mice and this presence was not affected by ageing but
augmented by the high fat diet. With deletion of ApoE, relaxations to iloprost
were potentiated but relaxations to acetylcholine and UK14304 were inhibited;
the greater iloprost-induced relaxations were not associated with changes in
protein presence of IP and TP receptors. Deletion of ApoE also unmasked an
L-NAME-resistant response to iloprost in the ageing group and prevented
the impact of high fat diet on relaxations to IP receptor stimulation. The
latter is likely through inhibition of TP receptor activation since the presence
of IP receptors was not different between wild-type and ApoE-/- mice after 29
weeks of high-fat diet.
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OP3.
EXERCISE AMELIORATES ENDOTHELIAL DYSFUNCTION
IN TYPE2-DIABETIC MICE THROUGH INCREASING
MicroRNA-181b LEVEL VIA AMPK PATHWAY
WB Shang, L Wang, JY Luo, XY Tian, Y Huang
School of Biomedical Sciences and Institute of Vascular Medicine, Chinese
University of Hong Kong, Hong Kong
Background and Purpose: Endothelial dysfunction plays an essential role
in the pathogenesis of diabetic vascular diseases. Our previous studies showed
that exercise ameliorates endothelial dysfunction by inhibiting ER stress and
increasing NO production. AMPK is one of the mediators for the beneficial
effect of exercise in vasculature. MicroRNA 181b (miR-181b) was reported
to improve glucose homeostasis and insulin sensitivity by regulating
endothelial function. However, whether miR-181b is regulated by exercise
and AMPK remains largely unclear. Therefore, we aim to investigate the
regulation of miR-181b expression by exercise and AMPK and the role of
miR-181b in mediating the beneficial effect of exercise.
Methods and Results: To investigate whether exercise upregulates miR181b expression, db/db mice were subjected to treadmill exercise for 45 min
per day for two months. Thereafter, mouse aorta was dissected for real-time
PCR. The results show that exercise significantly increases miR-181b
expression in mouse aorta compared to that from control mouse. To examine
the impact of blood flow on miR-181b, human umbilical vein endothelial
cells (HUVECs) exposed to laminar flow in a constant speed at 12 dyn/cm
for 24 hours exhibited a dramatically increase of miR-181b expression.
To understand the mechanism of miR-181b induction by laminar flow,
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) used to treat
HUVECs in three separate time points (2, 4, 8 h) significantly induces miR181b expression and peaks at 8 h. To examine whether miR-181b has

beneficial effect on endothelial function, we over-expressed the miR-181b
with adenovirus. The result show miR-181b over-expression improves
endothelial function in db/db mice accompanied with decreased vascular
inflammation and increased eNOS expression in mouse arteries.
Conclusion: Exercise ameliorates endothelial dysfunction at least in part
through increasing miR-181b level probably via AMPK pathway while miR181b improves endothelial function in diabetic mice by inhibiting vascular
inflammation and increasing eNOS expression. MiR-181b may serve as a
therapeutic target for treatment of diabetic vasculopathy (supported by RGCCRF and CUHK Direct Grant).

OP4.
DELETION OF RAP1 AGGRAVATES THE DEVELOPMENT
OF ATHEROSCLEROSIS IN APOLIPOPROTEIN
E-DEFICIENT MICE
XY Chen, EHC Tang
Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine,
The University of Hong Kong, Hong Kong

arches and abdominal aortas were assessed. In summary, our data demonstrate
that deletion of Rap1 promotes the development of atherosclerotic lesions in
ApoE-/- mice by increasing the plasma lipid level and lipid retention, as well
as plaque burden in aortic roots, aortic arches and abdominal aortas.

Repressor activator protein 1 (Rap1) normally docks to the ends of telomeres
and function to regulate telomere length and its structural integrity. However,
it is now known that Rap1 is able to move onto the chromosome arms or into
the cytoplasm and exert many other physiological functions. Recent data
from our lab shows that Rap1 is highly expressed in human atherosclerotic
lesions and Rap1 promotes the formation of macrophage foam cells. These
findings suggest that Rap1 may play an important role in atherosclerosis
development. We crossed Rap1 knockout mice with ApoE knockout mice to
generate Rap1 -/- ApoE -/- double knockout mice (DKO, on a C57BL/6
background) to unveil the importance of Rap1 in atherogenesis. DKO and
ApoE-/- (control) mice were subjected to a high fat high cholesterol diet.
After 10 weeks of feeding, the body weights of DKO mice were similar to
that of control mice. However, plasma cholesterol and triglyceride levels
were significantly increased in DKO mice as compared to control mice.
When lesion formation was assessed in frozen section of aortic root using
oil red O staining, significantly larger lesion area (control 19.8±0.7% vs.
DKO 34.7±2.3%; n=5-6; P<0.001) and lipid deposition area (control
53.2±1.9% vs. DKO 78.3±1.8%; n=5-6; P<0.001) were observed in DKO
mice. Similar conclusions were obtained when oil red O stained aortic
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OP5.
PHARMACOLOGIC INHIBITION OF FOXO1 IMPROVES
CARDIAC FUNCTION BY AMELIORATING EXCESSIVE
MITOPHAGY IN TYPE 1 DIABETIC RATS
D Yan, JR Luo, ZY Xia
Faculty of Medicine, The University of Hong Kong, Hong Kong
Objective: Diabetic cardiomyopathy (DCM) is a heart muscle disorder with
significant morbidity and mortality in diabetes. Forkhead transcriptional factor
(FOXO1) is aberrantly active in Type2 Diabetic mice and triggers the
development of DCM. Furthermore, endogenous FOXO1 has been suggested
to exacerbate autophagy of mitochondria (mitophagy), which is a critical
process for degradation of damaged mitochondria, and maintain
cardiomyocyte health under normal condition. However, the role of excessive
mitophagy in the pathogenesis of DCM is less studied and the link between
FOXO1 over-activation and mitophagy in diabetic heart has not been
investigated. Thus, we set out to investigate whether pharmacologic inhibition
of FOXO1 can attenuate DCM in type 1 diabetic rats and the underlying
mechanism.
Methods: Streptozotocin (STZ)-induced Type 1 diabetic rats (4 weeks after
STZ injection) were administered with 10% hydroxypropyl-b-cyclodextrin
with/without AS1842856 (FOXO1 selective inhibitor, 50 mg/kg) by oral
gavage twice daily for one week. On the day of harvest, the left ventricular
(LV) functions of the rats were assessed by Pressure-volume (PV) loop analysis
and the heart tissue were collected for protein analysis, etc. We used western
blot to detect FOXO1, P-FOXO1(S256), LC3 II/I ratio (index of autophagy),
as well as mitophagy-related protein (pink1, parkin, BECLIN1, BNIP3),
mitochondrial fusion-mediated protein (mitofusin1, mitofusin2), etc.

Results: PV loop analysis indicated that heart rate (bpm), LV ejection fraction
(%), -dp/dt min (mm Hg/s) were all significantly reduced in diabetic (D) rats
when compared with control (C) rats (all P<0.05). Biochemically, FOXO1
activity (decreased P-FOXO1/FOXO1 ratio, increased FOXO1 nuclear
translocation), LC3 II/I ratio, pink1/parkin, BECLIN1, BNIP3, mitofusin1
and mitofusin2 all significantly increase whereas P62 was significantly reduced
in D rats (all P<0.05, vs. C rats). The above results indicate mitophagy is
excessively activated in D rats that is concomitant with cardiac diastolic
dysfunction. Administration of FOXO1 inhibitor AS1842856 significantly
inhibited FOXO1 activity (increased P-FOXO1/FOXO1 ratio, decreased
FOXO1 nuclear translocation), improved cardiac function and reverted all
the above mentioned diabetes-induced biochemical changes except the
changes in BECLIN1 and BNIP3.
Conclusion: Pharmacologic inhibition of FOXO1 and the subsequent
downregulation of pink1/parkin and mitigating mitophagy over-activation
may represent major mechanism whereby inhibition of FOXO1 improves
cardiac function in early stage of DCM in Type 1 diabetic rats and may provide
a promising therapeutic target to treat the disease.

OP6.
ROLE OF SERUM EXOSOMES IN REGULATING
ENDOTHELIAL FUNCTION IN DIABETES
Y Wang, H Zhang, J Liu, D Qu, Y Huang, X Tian, L Wang, Y Huang
School of Biomedical Sciences and Institute of Vascular Medicine, Chinese
University of Hong Kong, Hong Kong

Conclusions: The present results suggest that serum exosomes inhibit NO
production and impair endothelial function in mouse aorta. Serum exosomes
also impair vascular integrity by altering the tight junction composition, which
might contribute to diabetes-associated microvascular complications
(supported by RGC-CRF and RGC-GRF).

Objectives: Exosomes are abundant in blood, and the various molecules
contained in exosomes can be delivered to recipient cells via blood circulation.
Vascular endothelial cells are constantly exposed to circulating substances.
Therefore, we aim to investigate how endothelial cells respond to serum
exosomes and its implication in diabetes-associated vascular dysfunction.
Methods: Aortas were dissected and isometric force was measured in wire
myograph to test vascular function. To measure NO bioavailability, endothelial
cells were stained with NO-sensitive fluorescent dye and NO production was
detected by confocal microscopy. Expression of target genes were measured
by RT-PCR.
Results: The present study shows endothelial cell is able to take up PKH67labeled serum exosomes isolated from diabetic (db/db) mouse indicated by
increased incorporation of fluorescence into aortic endothelial cells. db/db
exosomes treatment reduced NO production in endothelial cells, and severely
impaired NO-dependent vascular relaxation in non-diabetic (db/m+) mice.
In addition, serum exosomes from db/db mouse and diabetic Zucker (fa/fa)
rat induced proliferation in primary cultured mouse and rat endothelial cells.
Yap target genes were activated in diabetic exosomes treated endothelial cells.
Screening of the tight junction proteins transcription shows significant
downregulation of Cldn1 and upregulation of Zo2 in diabetic exosomes treated
endothelial cells.
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ASSOCIATION BETWEEN BLOOD LEAD LEVEL AND
SYSTOLIC BLOOD PRESSURE: UNITED STATES NATIONAL
HEALTH NUTRITION AND EXAMINATION SURVEY
(NHANES) 1999-2014
MF Tsoi,1 TT Cheung,1 BMY Cheung1,2,3
1
Department of Medicine; 2 State Key Laboratory of Pharmaceutical
Biotechnology; 3Institute of Cardiovascular Science and Medicine, The
University of Hong Kong, Hong Kong

Conclusion: Blood lead level is associated with systolic blood pressure in
the general population, most of whom do not have elevated blood lead level.
Reducing lead in the environment not only benefits children but may also
benefit adults.
.

Introduction: Lead toxicity is an uncommon cause of hypertension. We
recently reported that blood lead level has declined in America. Therefore,
we examined if there is still an association between low blood lead level and
systolic blood pressure (SBP).
Methods: We included participants who had blood lead level and blood
pressure measurement in the National Health Nutrition and Examination
Survey 1999-2014. Results were analysed using SPSS complex sample module
version 22 with sample weight adjustment. We further analysed the association
between blood lead level and SBP in people with blood lead level <5 µg/dL
and in ethnic groups. We calculated regression coefficient and 95% confidence
interval for every 2.72 times increase in blood lead level.
Results: 20596 participants were included in this analysis. Every 2.72 times
increase in blood lead level was associated with increase of 4.98 [4.54-5.43]
mmHg in SBP (p<0.0001). This remained significant after adjusting for age,
gender, ethnicity and waist circumference (0.75 [0.30-1.20]; p=0.001). This
significant association was also found in participants with blood lead level
<5 µg/dL (5.59 [5.12-6.07]; p<0.0001) and in all ethnicities (Mexican
Americans: 4.14 [3.45-4.83]; p<0.0001; Other Hispanics: 4.93 [3.56-6.30];
p<0.0001; 6.04 [5.40-6.67]; p<0.0001; Non-Hispanic Blacks: 5.82 [4.956.68]; p<0.0001; Other Races: 3.28 [1.51-5.04]; p<0.0001).

OP8.
ROLE OF AMPK IN EDH-LIKE RELAXATIONS IN RAT
SUPERIOR MESENTERIC ARTERIES
H Chen, PM Vanhoutte, SWS Leung
Department of Pharmacology and Pharmacy, the University of Hong Kong,
Hong Kong
Introduction and Objective: Adenosine monophosphate-activated protein
kinase (AMPK) has beneficial effects on the vasculature, including facilitation
of vasodilatation. Endothelium-derived hyperpolarization (EDH) is one of
the major vasoactive signals generated by endothelial cells for the regulation
of vascular tone, in particular in resistance arteries which contribute to arterial
blood pressure regulation. Although the mechanism underlying EDH varies
with species and blood vessel type, activation of intermediate- and smallconductance calcium-activated potassium channels (IK Ca and SK Ca ,
respectively) in the endothelium followed by stimulation of Na+/K+-ATPase
and inwardly-rectifying potassium channels (Kir ) in the underlying vascular
smooth muscle, is a common characteristic of the EDH pathway. The present
study aimed to examine whether or not AMPK affects EDH-mediated
relaxations and, if so, to determine the mechanism(s) involved.
Methods: Male twelve-week-old Sprague Dawley (SD) rats were used.
Superior mesenteric arterial rings were suspended in conventional organ
chambers for isometric tension recording and were collected for measuring
the activity of AMPK.
Results: AICAR (AMPK activator; 10-4 M) significantly reduced acetylcholineinduced EDH-like relaxations in superior mesenteric arteries of SD rats;
the effect was restored by compound C (AMPK inhibitor; 10-5 M). AMPK
activity assays confirmed that AICAR (10-4 M) caused AMPK activation in
SD rat mesenteric arteries. Ouabain (inhibitor of Na+/K+-ATPase; 10-3 M),
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but not barium chloride (inhibitor of Kir ; 3 x 10-5 M), significantly reduced
acetylcholine-induced EDH-like relaxations. The inhibitory effects of ouabain
and AICAR on EDH-like relaxations were not additive. Similar results were
obtained with endothelium-dependent relaxations induced by SKA-31
(positive allosteric modulator of SKCa and IKCa channels; 10-5 M). In rings
without endothelium, potassium chloride (5 x 10-3 M)-induced relaxations
were abolished by ouabain but were not affected by AICAR.
Conclusions: Activation of AMPK reduces EDH-like relaxations in the rat
superior mesenteric artery, likely by inhibiting, at the endothelial level, the
IKCa-Na+/K+-ATPase signaling pathway.
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OP9.
UNDERSTANDING THE VASOPROTECTIVE EFFECTS OF
TETRAMETHYLPYRAZINE: NEW EVIDENCE FOR ANTI-ER
STRESS-DEPENDENT PREVENTION OF BKCa CHANNEL
DYSFUNCTION
WT Sun,1 XC Wang,1 SK Mak,1 GW He,2 Q Yang1,2
1
Division of Cardiology, Department of Medicine and Therapeutics, Institute
of Vascular Medicine, Li Ka Shing Institute of Health Sciences, Institute of
Innovative Medicine, Faculty of Medicine, The Chinese University of Hong
Kong, Hong Kong; 2TEDA International Cardiovascular Hospital, Chinese
Academy of Medical Sciences, China

improvement in BKCa channel-mediated dilatation of coronary arteries. The
anti-ER stress-dependent restoration of BKCa β1 by TMP may be attributable
to inhibition of FoxO3a-induced upregulation of ubiquitin ligases Murf-1
and atrogin-1.
Conclusions: This study revealed that TMP possesses anti-ER stress properties
and inhibition of BKCa β1 degradation by alleviating ER stress is involved in
the protective effects of TMP against homocysteine in the coronary
vasculature.
Supported by RGC/GRF CUHK14118414; Lui Che Woo Institute of Innovative
Medicine - CARE theme 8303303, and CUHK Direct Grant 4054273.

Aim: We previously demonstrated that BKCa channel inhibition by ER stress
contributes to homocysteine-induced vascular dysfunction. In this study, we
investigated whether tetramethylpyrazine (TMP), an active ingredient of the
Chinese herb Chuanxiong, may protect BKCa channel function via an anti-ER
stress mechanism.
Methods: Porcine small coronary arteries were used. Isometric force study
was performed in endothelium-denuded arterial rings for the dilator function
of BKCa channels. Primary culture of coronary arterial smooth muscle cells
(PCASMCs) were used for determination of expressions of ER stress
molecules, BKCa channel subunits, and ubiquitin ligases, as well as recording
of BKCa channel currents.
Results: TMP showed significant inhibitory effect on ER stress in PCASMCs.
In cells exposed to homocysteine or the chemical ER stress inducer
tunicamycin, TMP significantly decreased expression of GRP78 and ATF6
and suppressed phosphorylation of PERK, eIF2α, and IRE1. Suppression of
ER stress by TMP was observed to restore the BKCa β1 protein level and
enhance the BK Ca channel current in PCASMCs, with a subsequent

OP10.
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE
REGULATOR REGULATES PANNEXIN 1 CHANNEL
OPENING FOR ACIDOSIS-INDUCED ATP RELEASE FROM
CARDIOMYOCYTES

induced ATP release, whereas forskolin- or lactic-acid-stimulated ATP release
was abolished by a caspase inhibitor. We propose that the CFTR Cl channel
opens during acidosis, allowing the movement of a signaling molecule into
the cell, which indirectly modulates Pannexin1 gating by activation of caspase.

Y Wang, HJ Ballard
The University of Hong Kong, Hong Kong
ATP is released in the heart under a variety of conditions, including hypoxia,
ischaemia and catecholamine stimulation. Under physiological conditions,
extracellular ATP, and its breakdown product, adenosine, contribute to local
vasodilation and regulation of coronary blood flow. We investigated the
mechanism of ATP release in cardiomyocytes isolated from adult rat heart.
Treatment with lactic acid produced pH depression and enhanced ATP release
from cardiomyocytes. On the other hand, simulated ischaemia (metabolic
inhibition plus anoxia) lowered ATP release. The acidosis-induced ATP release
was abolished by the specific CFTR inhibitor, CFTRinh-172, CFTR pore
blocker, GlyH-101, or CFTR siRNA, suggesting that CFTR was involved.
Forskolin and IBMX, agents that activate CFTR by elevating the intracellular
cAMP, also increased ATP release, confirming the role of CFTR. However,
blockade of Pannexin1 channels by Fast Green FCF, Brilliant Blue FCF, or
pannexin1 siRNA, attenuated the ATP release during acidosis or forskolin
treatment, and further lowered the ATP release during simulated ischaemia,
suggesting that Pannexin1 functions as the ATP release channel.
Immunofluorescence imaging suggested that CFTR and Pannexin1 were not
co-localized. An src tyrosine kinase inhibitor failed to modify the acidosis-
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OP11.
NON-INVASIVE NON-ALCOHOLIC FATTY LIVER DISEASE
(NAFLD) SCORES AND CARDIOVASCULAR DISEASES
(CVDs) IN THE UNITED STATES NATIONAL HEALTH AND
NUTRITION EXAMINATION SURVEY (NHANES) 1999-2014
CO Lee, MF Tsoi, CL Cheung, BMY Cheung
Department of Medicine, The University of Hong Kong, Hong Kong
Objectives: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent
in the Hong Kong population. Hence, it is important to identify the possible
complications. Whether NAFLD is a risk factor for cardiovascular diseases
(CVDs) is uncertain. We therefore analysed their association in this
crosssectional study.
Methods: Data from the United States National Health and Nutrition
Examination Survey (NHANES) 1999-2014 were analysed using the SPSS
complex sample module. A total of 11,427 non-pregnant adults without viral
hepatitis, self-reported insulin injection, prescription of anti-diabetic
medications and missing data were included in this analysis. By applying
binary logistic regression, four non-invasive NAFLD scores, fatty liver index
(FLI), NAFLD liver fat score (LFS), hepatic steatosis index (HSI) and lipid
accumulation product (LAP), were examined for association with CVD
outcomes, namely, coronary heart disease (CHD), myocardial infarction (MI),
heart failure (HF) and stroke.
Results: LFS was associated with increased risk of CHD (Odds ratio adjusted
for age, gender, ethnicity and high-density lipoprotein (HDL) level [95%
confidence interval]: 1.12 [1.06-1.17]), MI (1.09 [1.05-1.14]) and HF (1.09
[1.02-1.16]) with AUC of 0.595, 0.592, 0.590, respectively (p<0.0001 for these
outcomes). FLI was associated with increased risk of MI (1.01 [1.00-1.01])
and HF (1.01 [1.00-1.02]) with AUC of 0.594 (p=0.013), 0.616 (p<0.0001)

respectively. HSI was associated with increased risk of HF (1.03 [1.00-1.05]).
LAP was not associated with these three outcomes (CHD: 1.00 [1.00-1.00];
MI: 1.00 [1.00-1.00]; HF: 1.00 [1.00-1.00]). None of the NAFLD scores were
associated with stroke (FLI: 1.00 [1.00-1.01]; HSI: 1.01 [0.98-1.03]; LFS:
1.05 [0.99-1.11]; LAP: 1.00 [1.00-1.00]).
Conclusions: With a large study population, we could demonstrate a weak
association of NAFLD with CHD, MI and HF. Despite its high prevalence,
NAFLD is generally benign with only a slightly elevated risk for CVDs.

OP12.
NILOTINIB EXACERBATES DISTURBED FLOW-INDEUCED
ATHEROSCLEROSIS THROUGH FOCAL TLR4 ACTIVATION
D Qu, L Wang, W Song, M Huo, CW Lau, XY Tian, Y Huang
School of Biomedical Sciences and Institute of Vascular Medicine,
The Chinese University of Hong Kong, Hong Kong

Conclusions: Our findings suggest TLR4 inhibition as a therapeutic approach
to address the vascular safety issue of nilotinib, with its efficacy doublesecured by targeting both disturbed blood flow- and nilotinib-induced
endothelial inflammation.
(Supported by CUHK2/CRF/12G, GRF14105814, NSFC91339117 and CUHK
Lui Che Woo Foundation)

Objectives: The use of nilotinib (Tasigna), a second-generation tyrosine
kinase inhibitor for treating chronic myeloid leukemia, increases risk of
atherosclerosis. We aim to investigate the role of nilotinib in endothelial
function and atherosclerosis, and hope to identify a therapeutic strategy to
alleviate the vascular adverse effects of nilotinib.
Methods: Partial carotid ligation was performed in ApoE-/- mice to generate
disturbed flow and to induce atherogenesis in left common carotid in mice.
Proximity ligation assay was used to detect interaction between target proteins
in endothelial cells. HUVECs were transfected with TLR4 shRNA or nontarget shRNA by lentiviral vector and cells with stable expression of shRNA
were selected by puromycin.
Results: Here, we demonstrated that orally administered nilotinib profoundly
accelerated atherosclerosis plaques formation in ApoE-/- mice receiving carotid
partial ligation surgery. Co-administration of TLR4 inhibitor CLI-095 reversed
the pro-atherosclerotic effect of nilotinib. This reversal was achieved by two
TLR4-dependent mechanisms involved in endothelial inflammation. First, in
endothelial cells, nilotinib-induced inflammatory molecules expression and
monocyte attachment were inhibited by knockdown of TLR4 or CLI-095.
Second, disturbed flow per se activated TLR4, leading to endothelial
inflammation. Knockdown of TLR4 or CLI-095 administration suppressed
the disturbed flow-induced inflammation.
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OP13.
EFFECTS OF OUABAIN ON ENDOTHELIUM-DEPENDENT
RESPONSE
CR He, PM Vanhoutte, SWS Leung
Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine,
The University of Hong Kong, Hong Kong
Ouabain is an inhibitor of sodium-potassium adenosine triphosphatase (Na+/
K+-ATPase, also known as Na+ pumps). It is released by high sodium chloride
concentration from hypothalamus and adrenals. Upon released in the
circulation, it increases arterial constriction and hence blood pressure. Since
high circulating levels of sodium chloride and ouabain are likely present
concurrently, the present study aimed to examine whether or not sodium
affected the vascular effects of ouabain locally. Aortae were isolated from
male Sprague Dawley rats (8-12 weeks old) and incubated in the organ
chambers with modified Krebs-Henseleit solutions containing normal
(140 mM) or high (160 mM) sodium, in the absence or presence of different
contractions of ouabain (10-6, 10-4, 2 x 10-4, 5 x 10-4 M). They were contracted
with phenylephrine (10 -6.5 to 10 -5 M) and relaxed with increasing
concentrations of endothelium-dependent and -independent vasodilators,
acetylcholine (10-9 to 10-5 M) and DETA NONOate (10-9 to 10-3.5 M). Ouabain,
at 5 x 10 -4 M, decreased the relaxation to acetylcholine in rat aorta with
endothelium, and merely shifted the relaxation curve of DETA NONOate to
the right in preparations without endothelium. Ouabain caused greater
decrease in acetylcholine-induced relaxations under high sodium condition,
and in aortae incubated in solutions containing mannitol (40 mM), which
increased the osmolarity of the incubating solution to that similar to the
increased sodium chloride level (from 140 to 160 mM). The increased sodium
level or mannitol alone did not affect the relaxation to acetylcholine. The
results, therefore, suggested that elevation of extracellular osmolarity [by

high sodium concentration or mannitol] enhanced the inhibitory effect of
ouabain. In order to elucidate the mechanism(s) through which ouabain affect
relaxations, rat aortae were incubated without or with different concentrations
of ouabain and relaxations to arachidonic acid (AA) were examined. Ouabain
decreased AA-induced relaxation in aortae with endothelium, but not in those
without endothelium. The inhibition by ouabain was not observed in the
presence of indomethacin (cyclooxygenase inhibitor), L-NAME (nitric oxide
synthase inhibitor) or ODQ (soluble guanylyl cyclase inhibitor). These
findings suggested that ouabain likely inhibits endothelial cyclooxygenase
or nitric oxide synthase to reduce relaxation.

OP14.
CHLORIDE CHANNELS ARE INVOLVED IN THE
DEVELOPMENT OF ATRIAL FIBRILLATION −
A TRANSCRIPTOMIC AND PROTEOMIC STUDY
YY Jiang,1,2 HT Hou,1 Q Yang,1 XC Liu,1 GW He1,2,3
1
Department of Cardiovascular Surgery & Center for Basic Medical Research,
TEDA International Cardiovascular Hospital, The Chinese Academy of
Medical Sciences & Nankai University, Tianjin, China; 2The Affiliated
Hospital of Hangzhou Normal University & Zhejiang University, Hangzhou,
China; 3Department of Surgery, Oregon Health and Science University,
Portland, Oregon, U.S.A.

microscope analysis, the excess type IV collagen was deposited around
myocytes and was upregulated in the left atrium tissue of the AF patients. In
addition, by protein structure prediction and co-immunoprecipitation, there
was a possible interaction between CLICs and type IV collagen.
Conclusions: These results for the first time indicate that CLICs play an
important role in the development of AF and that CLICs and structural type
IV collagen may interact on each other to promote the development of AF.
These findings may lead to the new direction for mechanisms of AF and
reveal new drug targets.

Objectives: The exact pathogenic factors of atrial fibrillation (AF) are
unknown. We investigated the AF-related pathogenic factors at the mRNA,
protein, and structure levels by using multiple approaches.
Methods: Transcriptomic (RNA-Seq) and proteomic (iTRAQ) techniques
were applied to investigate the left and right atrial tissue collected from 62
patients with rheumatic mitral valve disease in either persistent AF or sinus
rhythm (SR) undergoing valve replacement procedures.
Results: The up-regulated expression of CLIC1, CLIC4, CLIC5 proteins was
detected in AF patients (p<0.05), especially in the left atrial tissue. These
were in accordance with the change of mRNA of these CLICs and were verified
by western blot and qRT-PCR. The bioinformatic analysis suggested the
involvement of CLICs in biological process, cell component, and molecular
function in AF patients. Immunofluorescence staining disclosed that CLIC1,
CLIC4, and CLIC5 were expressed on myocardial membrane and organelles.
Combined with the results from immunohistochemistry and electron
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RANDOMIZED CONTROLLED TRIAL OF
PHYTOSTEROLS IN A ONCE-DAILY SOYA DRINK IN
NORMOCHOLESTEROLAEMIC CHINESE
CL Cheung, 1,2,3 YC Cheng, 1 YP Chau, 1 MF Tsoi, 2 VK Cheng, 2 GK Lee, 2
BMY Cheung2,3
1
Department of Pharmacology and Pharmacy; 2Department of Medicine; 3State
Key Laboratory of Pharmaceutical Biotechnology; University of Hong Kong,
Hong Kong
Introduction: Phytosterols reduce intestinal cholesterol absorption and help
to lower LDL-cholesterol (1). Many Chinese adults have lactose intolerance
and cannot tolerate phytosterol added to cow's milk. We therefore conducted
a randomized double-blind controlled trial to assess the efficacy and tolerability
of a phytosterol-fortified soya drink in lowering serum LDL-cholesterol.
Method: Two hundred and one normocholesterolaemic healthy adult
participants (100 men and 101 women; age 19-79) were randomized to daily
intake for three weeks of one pack of phytosterols-enriched soya drink that
contained 2 g phytosterols per day (N=100) or a matched soya drink without
phytosterols (N=101). The primary outcome variable was the serum LDLcholesterol. Adverse events, withdrawal and compliance were documented.
The study protocol received ethical approval and was registered (ClinicalTrials.
gov identifier: NCT02881658; Date of registration: 14 Aug 2016). All
participants gave written informed consent. Data management and intentionto-treat analysis were carried out by an accredited Clinical Trials Centre and
an independent statistician respectively.
Results: Only seven participants did not complete the study. The compliance
(mean±SD) was 99.6±6.9% and 99.2±6.3% in the treatment and control group
respectively. Serum cholesterol decreased by 6.6%, from 2.9±0.96 to 2.71±
0.83 mmol/L (mean±SD), in the treatment group; and by 1.6%, from
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2.83±0.81 to 2.75±0.79 mmol/L, in the control group. Compared to control,
phytosterols reduced serum LDL-cholesterol (mean±SE) by 0.13±0.06 mmol/L
(p=0.02). There were no significant changes in body weight, waist
circumference, blood pressure, blood glucose or other lipid parameters such
as HDL and triglycerides. Ninety-five percent of the participants randomised
to the fortified drink reported no adverse events at all. Of the six adverse
events, five were intestinal symptoms. There were no serious adverse events.
Conclusion: The phytosterol-fortified soya drink reduced LDL-cholesterol
and was well-tolerated. This nonpharmacological way of lowering LDLcholesterol is suitable for people in the general population who have not yet
developed cardiovascular disease or cardiovascular risk factors.
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GINKGO BILOBA EXTRACT PROTECTS AGAINST
MYOCARDIAL INJURY THROUGH ATTENUATION
ENDOPLASMIC RETICULUM STRESS IN STZ -INDUCED
DIABETIC APOE-/- MICE
JF Tian,1,2 YF Liu,3 W Wang,1 Y Liu,2 K Chen2
1
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical
University; 2Cardiovascular Disease Centre, Xiyuan Hospital, China Academy
of Chinese Medical Sciences; 3Graduate School, Beijing University of Chinese
Medicine, Beijing, China
Objectives: It is known that cardiomyocytes apoptosis, interstitial fibrosis,
and intramyocardial inflammation are pathological characters of diabetic
myocardial injury. Traditional medicine Ginkgo biloba leave extrat (GBE)
exerts biological effects including scavenging free radical, lowering oxidative
stress and anti-inflammation. Aim of the present study was to investigate the
cardio-protection effects of GBE against diabetic myocardial injury.
Methods: High-fat fed ApoE-/- mice were rendered diabetes by low dose of
streptozotocin (STZ) for 5 consecutive days. The diabetic ApoE-/- mice were
treated with 200 mg/kg or 400 mg/kg GBE by daily gastric gavage for 12
weeks. The diabetic ApoE-/- mice received saline served as untreated diabetic
group, and non-diabetic C57BL/6J mice served as control group. HE,
MASSON and TUNEL staining were performed to analysis myocardial tissue
morphological changes. Immunohistochemical staining for cleaved caspase3 was used to analysis cardiomyocytes apoptosis. Collagen I and III mRNA
contents were determined by real time PCR. NF-κB expression, TNF-α and

IL-β mRNA contents were determined to analysis the intramyocardial
inflammation. Hallmarks of endoplasmic reticulum stress (ERS)-related
apoptosis pathways including phosphorylated c-Jun N-terminal kinase
(p-JNK), CHOP, caspase-12 and cleaved caspase-3 were analysised by Western
blot.
Results: Diabetic ApoE-/- myocardial injury was associated with increased
cardiomyocytes apoptosis, intramyocardial inflammation and interstitial
fibrosis. Immunohistochemical staining revealed increased expression of
cleaved caspase-3 in untreated diabetic myocardium. Collagen I and III mRNA
contents were significantly increased in untreated diabetic heart. NF-κB
expression, TNF-α and IL-1β mRNA contents which represent intramyocardial
inflammation were increased in untreated diabetic ApoE-/- heart. Expression
of hallmarks of ERS-related apoptosis pathways including p-JNK, CHOP,
caspase-12 and cleaved caspase-3 were significantly elevated in untreated
diabetic myocardial tissue compared to that in control group (P<0.05). GBE
both at 200 mg/kg/d and 400 mg/kg/d significantly blunt the myocardial
collage deposition, cardiomyocytes apoptosis and intramyocardial
inflammation within diabetic heart, associated with inhibition of p-JNK,
CHOP and caspase-12 pathways, accompanied by decreased serum
inflammation cytokines IL-6, IL-1β and TNF-α. Regulation effect of blood
glucose and lipid profiles was also manifested in the present study.
Conclusion: Our data demonstrate that myocardial protection effects of GBE
involves attenuation of ERS-related apoptosis under diabetic conditions,
indicating that GBE treatment might be beneficial in diabetic myocardial
injury.

P02.
EFFECTS OF AN AQUATIC PHYSIOTHERAPY PROGRAM ON
CARDIOVASCULAR OUTCOMES AND FUNCTIONAL
AEROBIC CAPACITY IN OLDER ADULTS WITH
OSTEOARTHRITIS OF THE KNEE: A RANDOMISED
CONTROLLED TRIAL
SSM Fong,1 X Guo,2 LKY Wong,3 YM Ng,3 JWY Chung4
1
School of Public Health, The University of Hong Kong; 2Department of
Rehabilitation Sciences, The Hong Kong Polytechnic University; 3The Hong
Kong Society for Rehabilitation; 4Department of Health and Physical Education,
The Education University of Hong Kong, Hong Kong

Results: Intention-to-treat analysis revealed that resting heart rate increased
in the aquatic-exercise group and decreased in the control group after training
(p=0.030). In addition, the resting diastolic blood pressure decreased
exclusively in the control group overtime (p=0.013). No significant group,
time or group-by-time interaction effects were noted in all other outcomes.
Conclusions: The aquatic exercise program was not effective in improving
cardiovascular outcomes and functional aerobic capacity of older adults with
OA of the knee.
(Funding: The Education University of Hong Kong RG10/2012-2013R)

Objectives: This study aimed to evaluate the efficacy of a novel aquatic
exercise program on resting heart rate, resting blood pressure and functional
aerobic capacity in a population with osteoarthritis (OA) of the knee.
Methods: This was a randomised, single-blinded, controlled trial. Eightythree older adults with OA of the knee were randomly assigned to either an
aquatic-exercise group (n=31; mean age±SD=56.2±9.8 years) or a control
group (n=52; mean age±SD=61.4±10.7 years). The aquatic-exercise group
received physiotherapist-designed aquatic exercise training 1-hour per week
for 10 weeks along with advice on self-care. The control group received selfcare advice only. Measurements were taken before and after the aquatic
intervention. Primary outcomes were resting heart rate and blood pressure.
Secondary outcome was total distance covered in a six-minute walk test.
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ARTERIAL WALL STRESS INDUCES ATHEROSCLEROSIS
IN VASCULAR REMODELLING BY ACTIVATING YAP/TAZ
EXPRESSION
YS Wang,1,3 JJ Liu2,3
Department of Pharmacology, The University of Hong Kong; 2Department
of Anaesthesiology, The University of Hong Kong, Hong Kong; 3Department
of Cardiology, The Second Affiliated Hospital of Harbin Medical University,
Harbin, China

1

The increasing wall stress or biomechanical stretch as it is experienced by
arteries influence the initiation of atherosclerotic lesions. Yes-associated
protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ),
effectors of the Hippo pathway, have been identified as mediators for
mechanical stimuli. Herein, the purpose of this research is to investigate the
functional role of YAP/TAZ in the stretch regulation programs HUASMCs
to a proliferative phenotype and the consequential development of
atherosclerotic lesions. We reported that the YAP/TAZ activation controls
critical aspects of the VSMCs phenotype and is activated by biomechanical
stretch. YAP/TAZ knockdown significantly attenuated the VSMCs
proliferative and proinflammatory phenotypes in the regulation of
biomechanica stretch. In addition, treatment with atorvastatin, an
antiatherosclerotic drug, inhibited YAP/TAZ expression and nuclear
traslocation. Then, we showed that stretch inhibits the Hippo pathway through
activation of PI3-kinase (PI3K) and phosphoinositide-dependent kinase
(PDK1), but independent of AKT activity. These findings show that an
important activity of YAP/TAZ by biomechanical stretch promoting
atheroprone phenotypes and atherosclerotic lesion development. Taken
together, our results indicate that inhibition of YAP/TAZ activation holds
promise antiatherogenesis therapeutic strategy.

P04.
KNOCKDOWN OF TM9SF4 TRIGGERING ER STRESS
EXERTS ANTI-GROWTH EFFECT ON DRUG-RESISTANT
BREAST CANCER CELLS
YF Zhu, XQ Yao
School of Biomedical Sciences, The Chinese University of Hong Kong,
Hong Kong
Introduction: Drug-resistance of chemotherapy is the leading cause of
mortality in breast cancer patients. Understanding how drug-resistant cancer
cell survival is of great importance for the breast cancer therapy. Here, we
identified a key protein, TM9SF4, namely transmembrane 9 superfamily,
isoform 4, which play vital role in drug-resistant breast cancer survival.
TM9SF4 is significantly up-regulated in drug-resistant breast cancer cells
MCF-7/ADM compared to its parental wildtype cell line MCF-7/WT.
Knockdown of TM9SF4 using lenti-TM9SF4-shRNA dramatically decreased
cell viability and induced cell death of MCF-7/ADM. Moreover, drug-resistant
xenografts derived from animal model also showed a significantly reduced
growth rate after the delivery of lenti-TM9SF4-shRNA. The underlying
mechanism appeared to be related to the triggering of ER stress via altered
ER Ca2+ content, leading to unfolded protein response, which will induce
apoptosis/necrosis, causing cell death. Our study provides TM9SF4 as a
promising target for the overcoming of drug-resistance in clinical breast cancer
therapy.
Objectives: To explore the underlying molecular and cellular mechanisms
of how TM9SF4 knockdown could reduce cell population growth of
chemoresistant MCF-7/ADM breast cancer cells.
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Methods:
Cell culture: Wild-type MCF-7 (MCF-7/WT) (ATCC) and MCF-7/ADM cells
were cultured. MCF-7/ADM cells were derived by exposing MCF-7 cells to
stepwise increasing concentrations of adriamycin over 8 months.
Western blot: Measurements of the protein level
CYQUANT assay and Edu assay: Cell viability and proliferation rate analysis
Immunofluorescence: Detection of the expression and distribution of
TM9SF4 and ER marker in breast cancer cells
Flow cytometry: Apoptosis/necrosis and aggresomes detection
Results: TM9SF4 expression level was up-regulated in drug-resistant MCF7 cells (MCF-7/ADM). Knockdown of TM9SF4 reduced MCF-7/ADM cell
proliferation rate and caused cell death. TM9SF4 could alter ER Ca2+ content.
Knockdown of TM9SF4 increased ER stress and protein misfolding in MCF7/ADM cells.
Conclusions: TM9SF4 is essential for drug-resistant breast cancer cell
survival. The underlying mechanism may involve ER stress induced by altered
ER Ca2+ content, which triggers unfolded protein response, inducing cell
apoptosis/necrosis. Our study provides TM9SF4 as a promising target in drugresistant breast cancer therapy.
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